Elena V. Kirilik
Elena V. Kirilik has a total of 36 co-authors. Here are the top co-authors by number of shared publications:
- Dmitry A. Dorofeev
Krasnov Research Institute of Eye Diseases
10 shared publications - Aleksandr A. Vitkov
Research Institute of Eye Diseases, Moscow, Russia
4 shared publications - Aleksandr V. Gorobets
South Ural State University (National Research University), Chelyabinsk, Russia
4 shared publications - Ksenia O. Lukyanova
Chelyabinsk Public Clinical Hospital No.2, Chelyabinsk, Russia
4 shared publications - Ol'GA G. Pozdeeva
Chelyabinsk Public Clinical Hospital No.2; South Ural State Medical University, Chelyabinsk, Russia
4 shared publications - Artem Z. Tsyganov
S.N. Fyodorov National Medical Research Center for Eye Microsurgery, Moscow, Russia
3 shared publications
Latest Publications
- 31 March 2025
- Published by LLC Science and Innovations in Russian Open Medical Journal
- Vol. 14 (1)
Changes in the ocular surface condition during the transition to preservative-free hypotensive combination therapy in the long-term observation of patients with advanced stages of glaucoma
Overview — Elevated intraocular pressure (IOP) is the main risk factor for the development and progression of primary open-angle glaucoma (POAG). Topical drugs, along with laser and surgical treatment options, are among the methods of IOP reduction. In most cases, topical hypotensive therapy is considered the first stage of glaucoma treatment. The transition to other treatment methods often occurs due to the ineffectiveness of long-term combination therapy. Most of the drugs used contain a preservative, which can negatively affect the condition of the ocular surface. The use of preservative-free fixed combinations (FC) can improve it with a similar hypotensive effect. Objective — To study the condition of the ocular surface when replacing the preserved FC of brinzolamide 1%/timolol 0.5% with a preservative-free FC of tafluprost 0.0015%/timolol 0.5%. Material and Methods — Group 1 (observation group) included patients with POAG in 20 (20.6%) eyes. Group 2 (control) included individuals without glaucoma who did not receive topical therapy in 77 (71%) eyes. The final study protocol included observational data at the time of inclusion in the study, as well as 1 month and 1 year after replacing the preserved FC of brinzolamide 1%/timolol 0.5% to the preservative-free FC of tafluprost 0.0015%/timolol 0.5%. All patients underwent a standard ophthalmological examination and assessment of structural and functional parameters, as well as examination of their ocular surface condition via the Norn test, Schirmer test, lissamine green vital staining, the Ocular Surface Disease Index (OSDI) questionnaire, and meniscometry 1 month and 1 year after the onset of the study. Results — Results: No statistically significant changes in IOP were observed after switching from the preserved FC of brinzolamide 1%/timolol 0.5% to the preservative-free FC of tafluprost 0.0015%/timolol 0.5% (from 13.4±2.7 to 13.4±3.2 mmHg after 1 month and to 15.3±4.4 mmHg after 1 year). At all checkpoints, the condition of the ocular surface was similar between the groups (p>0.05) for all parameters, except for the OSDI questionnaire. After 1 month and 1 year of observation, no significant changes in the ocular surface were found in the groups using preservative-free Tapticom ® (Santen, Japan), except for the OSDI questionnaire after 1 year. The ratio of the tear meniscus depth and height based on OCT meniscometry data statistically significantly differed between the groups. Conclusion — Long-term use of preservative-free Tapticom ® allowed effectively reducing the IOP to target values. This helped stabilizing structural and functional parameters without causing additional changes in the condition of the ocular surface. The transition from long-term treatment with preserved medications to preservative-free drug forms does not always lead to an improvement in the condition of the eyes. This may be due to a chronic process provoked by the preservative. Prescribing preservative-free therapy at the onset of treatment allows reducing the risk of developing dry eye syndrome and diminishing the subjective sensations in patients during long-term hypotensive therapy.
- 31 March 2025
- Published by LLC Science and Innovations in Russian Open Medical Journal
- Vol. 14 (1)
Changes in the ocular surface condition during the transition to preservative-free hypotensive combination therapy in the long-term observation of patients with advanced stages of glaucoma
Overview — Elevated intraocular pressure (IOP) is the main risk factor for the development and progression of primary open-angle glaucoma (POAG). Topical drugs, along with laser and surgical treatment options, are among the methods of IOP reduction. In most cases, topical hypotensive therapy is considered the first stage of glaucoma treatment. The transition to other treatment methods often occurs due to the ineffectiveness of long-term combination therapy. Most of the drugs used contain a preservative, which can negatively affect the condition of the ocular surface. The use of preservative-free fixed combinations (FC) can improve it with a similar hypotensive effect. Objective — To study the condition of the ocular surface when replacing the preserved FC of brinzolamide 1%/timolol 0.5% with a preservative-free FC of tafluprost 0.0015%/timolol 0.5%. Material and Methods — Group 1 (observation group) included patients with POAG in 20 (20.6%) eyes. Group 2 (control) included individuals without glaucoma who did not receive topical therapy in 77 (71%) eyes. The final study protocol included observational data at the time of inclusion in the study, as well as 1 month and 1 year after replacing the preserved FC of brinzolamide 1%/timolol 0.5% to the preservative-free FC of tafluprost 0.0015%/timolol 0.5%. All patients underwent a standard ophthalmological examination and assessment of structural and functional parameters, as well as examination of their ocular surface condition via the Norn test, Schirmer test, lissamine green vital staining, the Ocular Surface Disease Index (OSDI) questionnaire, and meniscometry 1 month and 1 year after the onset of the study. Results — Results: No statistically significant changes in IOP were observed after switching from the preserved FC of brinzolamide 1%/timolol 0.5% to the preservative-free FC of tafluprost 0.0015%/timolol 0.5% (from 13.4±2.7 to 13.4±3.2 mmHg after 1 month and to 15.3±4.4 mmHg after 1 year). At all checkpoints, the condition of the ocular surface was similar between the groups (p>0.05) for all parameters, except for the OSDI questionnaire. After 1 month and 1 year of observation, no significant changes in the ocular surface were found in the groups using preservative-free Tapticom ® (Santen, Japan), except for the OSDI questionnaire after 1 year. The ratio of the tear meniscus depth and height based on OCT meniscometry data statistically significantly differed between the groups. Conclusion — Long-term use of preservative-free Tapticom ® allowed effectively reducing the IOP to target values. This helped stabilizing structural and functional parameters without causing additional changes in the condition of the ocular surface. The transition from long-term treatment with preserved medications to preservative-free drug forms does not always lead to an improvement in the condition of the eyes. This may be due to a chronic process provoked by the preservative. Prescribing preservative-free therapy at the onset of treatment allows reducing the risk of developing dry eye syndrome and diminishing the subjective sensations in patients during long-term hypotensive therapy.
- 30 September 2024
- Published by LLC Science and Innovations in Russian Open Medical Journal
- Vol. 13 (3)
Reproducibility Of Retinal Nerve Fiber Layer And Macular Volume Measurements In Patients Receiving Retinal Protection Pharmacotherapy
Background — High-quality monitoring of the glaucoma plays an important role in the early diagnosis and treatment of glaucoma, for which structural optical coherence tomography (OCT) is used. Technology that increases the repeatability and reproducibility of OCT may differ in different devices, thereby yielding different results. Objective — To assess the effect of the frequency of retinal protection pharmacotherapy courses on quantitative data regarding the macular volume and the thickness of the retinal nerve fiber layer (RNFL) measured by two instruments, SPECTRALIS and OPTOPOL, and also to evaluate the agreement between the data collected by these devices. Material and Methods — We monitored 17 patients (34 eyes) diagnosed with primary open-angle glaucoma in the advanced stage from 2019 to 2023. Group 1 including 9 patients (18 eyes) received a course of retinal protection pharmacotherapy with Retinalamin® at an interval of 3 months, while Group 2 comprising 8 patients (16 eyes) received similar treatment at an interval of 6 months. All observed patients underwent structural OCT on REVO NX (OPTOPOL Technology) and SPECTRALIS devices at the onset of the study, as well as after 3 and 6 months. Results — The agreement between the two devices in measuring RNFL thickness was estimated by the Lin’s concordance correlation coefficient (LCCC): in manual mode, LCCCstart=0.69 (95% CI: 0.51-0.81); while in automatic mode, LCCCstart=0.73 (95% CI: 0.57-0.84). The agreement between the macular volume measurements was as follows: in manual mode, LCCCstart=0.21 (95% CI: 0.21-0.29); while in automatic mode, LCCCstart=0.21 (95% CI: 0.21-0.29). Conclusion — The agreement between the SPECTRALIS and OPTOPOL devices in terms of RNFL thickness should be considered substantial, while in terms of macular volume, it should be classified as fair. As measured in the manual mode, the RNFL thickness in both groups receiving Retinalamin increased, which can be interpreted as a favorable effect of retinal protection pharmacotherapy.
- 30 September 2024
- Published by LLC Science and Innovations in Russian Open Medical Journal
- Vol. 13 (3)
Reproducibility Of Retinal Nerve Fiber Layer And Macular Volume Measurements In Patients Receiving Retinal Protection Pharmacotherapy
Background — High-quality monitoring of the glaucoma plays an important role in the early diagnosis and treatment of glaucoma, for which structural optical coherence tomography (OCT) is used. Technology that increases the repeatability and reproducibility of OCT may differ in different devices, thereby yielding different results. Objective — To assess the effect of the frequency of retinal protection pharmacotherapy courses on quantitative data regarding the macular volume and the thickness of the retinal nerve fiber layer (RNFL) measured by two instruments, SPECTRALIS and OPTOPOL, and also to evaluate the agreement between the data collected by these devices. Material and Methods — We monitored 17 patients (34 eyes) diagnosed with primary open-angle glaucoma in the advanced stage from 2019 to 2023. Group 1 including 9 patients (18 eyes) received a course of retinal protection pharmacotherapy with Retinalamin® at an interval of 3 months, while Group 2 comprising 8 patients (16 eyes) received similar treatment at an interval of 6 months. All observed patients underwent structural OCT on REVO NX (OPTOPOL Technology) and SPECTRALIS devices at the onset of the study, as well as after 3 and 6 months. Results — The agreement between the two devices in measuring RNFL thickness was estimated by the Lin’s concordance correlation coefficient (LCCC): in manual mode, LCCCstart=0.69 (95% CI: 0.51-0.81); while in automatic mode, LCCCstart=0.73 (95% CI: 0.57-0.84). The agreement between the macular volume measurements was as follows: in manual mode, LCCCstart=0.21 (95% CI: 0.21-0.29); while in automatic mode, LCCCstart=0.21 (95% CI: 0.21-0.29). Conclusion — The agreement between the SPECTRALIS and OPTOPOL devices in terms of RNFL thickness should be considered substantial, while in terms of macular volume, it should be classified as fair. As measured in the manual mode, the RNFL thickness in both groups receiving Retinalamin increased, which can be interpreted as a favorable effect of retinal protection pharmacotherapy.
- Open Access
- 12 May 2023
- Published by Research Institute of Eye Diseases in National Journal glaucoma
- Vol. 22 (2) , 29-37
Artificial intelligence in ophthalmology. Do we need risk calculators for glaucoma development and progression?
Artificial intelligence (AI) is rapidly entering modern medical practice. Many routine clinical tasks, from imaging and automated diagnostics to robotic surgery, cannot be imagined without the use of AI. Neural networks show impressive results when analyzing a large amount of data obtained from standard automated perimetry, optical coherence tomography (OCT) and fundus photography. Currently, both in Russia and abroad mathematical algorithms are being developed that allow detection of glaucoma based on certain signs. This article analyzes the advantages and disadvantages of employing artificial intelligence in ophthalmological practice, discusses the need for careful selection of the criteria and their influence on the accuracy of calculators, considers the specifics of using mathematical analysis in suspected glaucoma, as well as in an already established diagnosis. The article also provides clinical examples of the use of glaucoma risk calculator in the routine practice of an ophthalmologist.
- 12 May 2023
- Published by Research Institute of Eye Diseases in National Journal glaucoma
- Vol. 22 (2) , 29-37
Open AccessArtificial intelligence in ophthalmology. Do we need risk calculators for glaucoma development and progression?
Artificial intelligence (AI) is rapidly entering modern medical practice. Many routine clinical tasks, from imaging and automated diagnostics to robotic surgery, cannot be imagined without the use of AI. Neural networks show impressive results when analyzing a large amount of data obtained from standard automated perimetry, optical coherence tomography (OCT) and fundus photography. Currently, both in Russia and abroad mathematical algorithms are being developed that allow detection of glaucoma based on certain signs. This article analyzes the advantages and disadvantages of employing artificial intelligence in ophthalmological practice, discusses the need for careful selection of the criteria and their influence on the accuracy of calculators, considers the specifics of using mathematical analysis in suspected glaucoma, as well as in an already established diagnosis. The article also provides clinical examples of the use of glaucoma risk calculator in the routine practice of an ophthalmologist.
- 20 December 2022
- Published by LLC Science and Innovations in Russian Open Medical Journal
- Vol. 11 (4)
Discomfort During Instillation Of Antihypertensives And Ocular Surface Condition In Glaucoma Patients
Background — An increase in the frequency of manifestations of dry eye syndrome (DES), against the background of hypotensive therapy, leads to a decrease in treatment adherence. After reformulation in the composition of a preservative-free preparation of a carbonic anhydrase inhibitor (CAI) (sodium benzoate was added), patient complaints of burning sensation during instillation became more frequent, which was the reason for our study. Objective — To evaluate the effect of sodium benzoate on the course of DES during local hypotensive therapy of glaucoma. Methods and Results — Group 1 consisted of 21 eyes with glaucoma receiving hypotensive therapy, Group 2 (20 eyes) included patients with suspected glaucoma not receiving therapy. Patients underwent standard diagnostic methods and examination of the ocular surface condition: tear break-up time test sensu Norn, Schirmer test, vital staining with lissamine green, and a survey based on the Ocular Surface Disease Index (OSDI) questionnaire. When a preservative-free CAI in combination therapy was replaced with the CAI containing sodium benzoate, no statistically significant change in IOP occurred after four weeks of treatment (p> 0.05). In both groups, the indicators characterizing the ocular surface condition did not change statistically significantly over the observation period. Conclusion — Replacement of preservative-free CAI in combination therapy of glaucoma with CAI with sodium benzoate does not lead to statistically significant changes in intraocular pressure. The ocular surface condition does not change statistically significantly over a month of observation. Instillation discomfort is not related to the pH of the preparation.
- 20 December 2022
- Published by LLC Science and Innovations in Russian Open Medical Journal
- Vol. 11 (4)
Discomfort During Instillation Of Antihypertensives And Ocular Surface Condition In Glaucoma Patients
Background — An increase in the frequency of manifestations of dry eye syndrome (DES), against the background of hypotensive therapy, leads to a decrease in treatment adherence. After reformulation in the composition of a preservative-free preparation of a carbonic anhydrase inhibitor (CAI) (sodium benzoate was added), patient complaints of burning sensation during instillation became more frequent, which was the reason for our study. Objective — To evaluate the effect of sodium benzoate on the course of DES during local hypotensive therapy of glaucoma. Methods and Results — Group 1 consisted of 21 eyes with glaucoma receiving hypotensive therapy, Group 2 (20 eyes) included patients with suspected glaucoma not receiving therapy. Patients underwent standard diagnostic methods and examination of the ocular surface condition: tear break-up time test sensu Norn, Schirmer test, vital staining with lissamine green, and a survey based on the Ocular Surface Disease Index (OSDI) questionnaire. When a preservative-free CAI in combination therapy was replaced with the CAI containing sodium benzoate, no statistically significant change in IOP occurred after four weeks of treatment (p> 0.05). In both groups, the indicators characterizing the ocular surface condition did not change statistically significantly over the observation period. Conclusion — Replacement of preservative-free CAI in combination therapy of glaucoma with CAI with sodium benzoate does not lead to statistically significant changes in intraocular pressure. The ocular surface condition does not change statistically significantly over a month of observation. Instillation discomfort is not related to the pH of the preparation.
- 25 June 2022
- Published by LLC Science and Innovations in Russian Open Medical Journal
- Vol. 11 (2)
Intravitreal Systems For Targeted Drug Delivery To The Posterior Eye Segment: A Systematic Review
Background — Intravitreal implants solve a number of serious problems arising in diseases of the posterior segment of the eyeball. Unlike intravitreal injections, the implant provides a prolonged release of a pharmaceutical drug over time. The review presents the characteristics of existing systems for intravitreal drug delivery: nanosystems, non-biodegradable and biodegradable implants. The review also highlights the main advantages and disadvantages of various implants. Based on the conducted literature review, the following conclusion is formulated: the most promising means of targeted drug delivery of drugs to the posterior segment of the eyeball are biodegradable implants. However, currently existing biodegradable implants do not provide entirely controlled release of the drug (uncontrollable extraction episodes occur at times), which constitutes a serious issue requiring improvement. Objective — to summarize the published data on existing systems for the targeted drug delivery into the vitreous chamber, identifying their major advantages and disadvantages. Material and Methods — Information was searched in such databases as PubMed, Google Scholar and ClinicalTrials.gov, using the keywords in both Russian and English languages: intravitreal implants, intraocular implants, biodegradable implants, non-biodegradable implants, nanosystems, nanoparticles, liposomes, targeted drug delivery, posterior segment of the eye, etc.
- 25 June 2022
- Published by LLC Science and Innovations in Russian Open Medical Journal
- Vol. 11 (2)
Intravitreal Systems For Targeted Drug Delivery To The Posterior Eye Segment: A Systematic Review
Background — Intravitreal implants solve a number of serious problems arising in diseases of the posterior segment of the eyeball. Unlike intravitreal injections, the implant provides a prolonged release of a pharmaceutical drug over time. The review presents the characteristics of existing systems for intravitreal drug delivery: nanosystems, non-biodegradable and biodegradable implants. The review also highlights the main advantages and disadvantages of various implants. Based on the conducted literature review, the following conclusion is formulated: the most promising means of targeted drug delivery of drugs to the posterior segment of the eyeball are biodegradable implants. However, currently existing biodegradable implants do not provide entirely controlled release of the drug (uncontrollable extraction episodes occur at times), which constitutes a serious issue requiring improvement. Objective — to summarize the published data on existing systems for the targeted drug delivery into the vitreous chamber, identifying their major advantages and disadvantages. Material and Methods — Information was searched in such databases as PubMed, Google Scholar and ClinicalTrials.gov, using the keywords in both Russian and English languages: intravitreal implants, intraocular implants, biodegradable implants, non-biodegradable implants, nanosystems, nanoparticles, liposomes, targeted drug delivery, posterior segment of the eye, etc.
- Open Access
- 16 June 2022
- Published by Real Time, Ltd. in Russian Ophthalmological Journal
- Vol. 15 (2 (Прил)) , 49-56
A method for measuring intraocular pressure using artificial intelligence technology and fixed-force applanation tonometry
Purpose. To estimate the accuracy of IOP measurement using artificial intelligence (AI) technologies and applanation tonometry with fixed strength. Material and methods. 290 patients (576 eyes) underwent applanation tonometry according to Maklakov with tonometer weights of 5, 10, and 15 g using a modified elastotonometry technique followed by an analysis of impression quality and diameter measurements by three independent ophthalmologist experts. The prints were then fed into a neural network to check the repeatability and reproducibility of the measurements. Results. The comparison of the diameters of the Maklakov tonometer prints determined by AI based on the neural network with the measurements data provided by three experts showed that neural network underestimates the measurement results by an average of 0.27 (-3.81; 4.35) mm Hg. At the same time, the intraclass correlation coefficient for all prints was 98.3%. The accuracy of diameter measurements of prints by neural network differs for tonometers of different weights, e.g. for a 5 g tonometer the difference was 0.06 (-3.38; 3.49) mm Hg, for 10 g and 15 g tonometers was 0.14 (-3.8; 3.51) and 0.95 (-3.84; 5.74) mm Hg, respectively. Conclusion. High accuracy and reproducibility of the measurements by the neural network, was shown to surpass the reproducibility of human-implemented measurements.
- 16 June 2022
- Published by Real Time, Ltd. in Russian Ophthalmological Journal
- Vol. 15 (2 (Прил)) , 49-56
Open AccessA method for measuring intraocular pressure using artificial intelligence technology and fixed-force applanation tonometry
Purpose. To estimate the accuracy of IOP measurement using artificial intelligence (AI) technologies and applanation tonometry with fixed strength. Material and methods. 290 patients (576 eyes) underwent applanation tonometry according to Maklakov with tonometer weights of 5, 10, and 15 g using a modified elastotonometry technique followed by an analysis of impression quality and diameter measurements by three independent ophthalmologist experts. The prints were then fed into a neural network to check the repeatability and reproducibility of the measurements. Results. The comparison of the diameters of the Maklakov tonometer prints determined by AI based on the neural network with the measurements data provided by three experts showed that neural network underestimates the measurement results by an average of 0.27 (-3.81; 4.35) mm Hg. At the same time, the intraclass correlation coefficient for all prints was 98.3%. The accuracy of diameter measurements of prints by neural network differs for tonometers of different weights, e.g. for a 5 g tonometer the difference was 0.06 (-3.38; 3.49) mm Hg, for 10 g and 15 g tonometers was 0.14 (-3.8; 3.51) and 0.95 (-3.84; 5.74) mm Hg, respectively. Conclusion. High accuracy and reproducibility of the measurements by the neural network, was shown to surpass the reproducibility of human-implemented measurements.
- 20 March 2022
- Published by LLC Science and Innovations in Russian Open Medical Journal
- Vol. 11 (1)
Perimetry Criteria For Assessing The Effectiveness Of Retinoprotective Therapy
Objective — To evaluate the effect of the frequency of retinoprotective therapy courses on perimetry parameters, to compare Octopus 900 perimeter with Octopus 600 perimeter, and to assess threshold perimetry results of G-dynamic versus 24-2 programs. Material and Methods — The study involved 17 patients (34 eyes) diagnosed with primary open-angle glaucoma of advanced stage. Group 1 included subjects receiving a course of Retinalamin every 3 months. Group 2 comprised patients undergoing Retinalamin therapeutics every 6 months. Results — At the onset of the study via G-dynamic and 24-2 programs, we did not observe any statistically significant differences between the groups in mean deviation of retinal photosensitivity (MD) and pattern standard deviation of mean retinal photosensitivity (PSD). However, the absolute values differed between groups and between programs. On average, the differences in MD and PSD values obtained in the photosensitivity study with G-dynamic vs. 24-2 programs were -0.36 dB (CI 95%: -4.27; 3.54) and 0.63 dB (CI 95%: 2.37; -1.11), respectively. Hence, studies performed via 24-2 and G-dynamic programs yielded comparable results (no statistically significant differences). However, they could not be identical due to different spatial arrangement of points in different programs. Conclusion — As a result of conducted treatment, retinal photosensitivity did not exhibit statistically significant changes; however, we observed positive dynamics in both groups in MD and PSD parameters of mean retinal photosensitivity. Different devices (Octopus 600 and Octopus 900 perimeters) and different programs (24-2, G-dynamic) yielded different outcomes due to their technical features and capabilities of reproducibility; however, these differences were not statistically significant.
- 20 March 2022
- Published by LLC Science and Innovations in Russian Open Medical Journal
- Vol. 11 (1)
Perimetry Criteria For Assessing The Effectiveness Of Retinoprotective Therapy
Objective — To evaluate the effect of the frequency of retinoprotective therapy courses on perimetry parameters, to compare Octopus 900 perimeter with Octopus 600 perimeter, and to assess threshold perimetry results of G-dynamic versus 24-2 programs. Material and Methods — The study involved 17 patients (34 eyes) diagnosed with primary open-angle glaucoma of advanced stage. Group 1 included subjects receiving a course of Retinalamin every 3 months. Group 2 comprised patients undergoing Retinalamin therapeutics every 6 months. Results — At the onset of the study via G-dynamic and 24-2 programs, we did not observe any statistically significant differences between the groups in mean deviation of retinal photosensitivity (MD) and pattern standard deviation of mean retinal photosensitivity (PSD). However, the absolute values differed between groups and between programs. On average, the differences in MD and PSD values obtained in the photosensitivity study with G-dynamic vs. 24-2 programs were -0.36 dB (CI 95%: -4.27; 3.54) and 0.63 dB (CI 95%: 2.37; -1.11), respectively. Hence, studies performed via 24-2 and G-dynamic programs yielded comparable results (no statistically significant differences). However, they could not be identical due to different spatial arrangement of points in different programs. Conclusion — As a result of conducted treatment, retinal photosensitivity did not exhibit statistically significant changes; however, we observed positive dynamics in both groups in MD and PSD parameters of mean retinal photosensitivity. Different devices (Octopus 600 and Octopus 900 perimeters) and different programs (24-2, G-dynamic) yielded different outcomes due to their technical features and capabilities of reproducibility; however, these differences were not statistically significant.
- Open Access
- 14 March 2022
- Published by Research Institute of Eye Diseases in National Journal glaucoma
- Vol. 21 (1) , 71-78
An effective model of clinical examination and monitoring of glaucoma patients
Open-angle glaucoma is a chronic progressive optic neuropathy characterized by morphological changes in the optic nerve head and retinal nerve fibers layer in the absence of other eye diseases.Regular medical check-ups are necessary to assess the progression of glaucoma, to correct the treatment regimen or prescribe surgical interventions, to control the stabilization of the glaucoma process and to preserve visual functions for longer period. When planning the number of monitoring visits, it is necessary to carefully study the prognostic risk factors, since they are statistically associated with the development and progression of glaucoma. Closer observation of patients with glaucoma reduces the risk of irreversible changes in the organ of vision.Patient compliance is of particular importance in the progression of glaucoma. The adherence rate in the treatment of glaucoma is relatively lower compared to other chronic diseases that require lifelong treatment.Currently, there is no effective model of regular checkups for glaucoma patients, therefore this direction requires improvement and development, both in the standards and timing of patient examination, and in the use of remote methods of glaucoma control. The disadvantage of the current medical check-ups routine is the lack of individual approach to patients, lack of equipment in the offices of regional ophthalmologists, and lack of specialized glaucoma offices.The tense epidemiological situation during the Covid-19 pandemic, gave understanding that while in-person consultations and remote consultations (telemedicine) cannot replace each other, a combination of these methods is cost-effective, can reduce the uneven distribution of ophthalmic resources, reduce the burden on the doctor and the rate of misdiagnosis. The situation was aggravated by the closure of ophthalmological hospitals and an increase in the waiting time for consultation in higher specialized medical institutions, which probably entails an increase in patients with progression of the glaucomatous process and the economic burden on both the state and the patients themselves.Telemedicine should be gradually introduced into everyday practice, for which it is advisable to create a single database of glaucoma patients to track the glaucomatous process.
- 14 March 2022
- Published by Research Institute of Eye Diseases in National Journal glaucoma
- Vol. 21 (1) , 71-78
Open AccessAn effective model of clinical examination and monitoring of glaucoma patients
Open-angle glaucoma is a chronic progressive optic neuropathy characterized by morphological changes in the optic nerve head and retinal nerve fibers layer in the absence of other eye diseases.Regular medical check-ups are necessary to assess the progression of glaucoma, to correct the treatment regimen or prescribe surgical interventions, to control the stabilization of the glaucoma process and to preserve visual functions for longer period. When planning the number of monitoring visits, it is necessary to carefully study the prognostic risk factors, since they are statistically associated with the development and progression of glaucoma. Closer observation of patients with glaucoma reduces the risk of irreversible changes in the organ of vision.Patient compliance is of particular importance in the progression of glaucoma. The adherence rate in the treatment of glaucoma is relatively lower compared to other chronic diseases that require lifelong treatment.Currently, there is no effective model of regular checkups for glaucoma patients, therefore this direction requires improvement and development, both in the standards and timing of patient examination, and in the use of remote methods of glaucoma control. The disadvantage of the current medical check-ups routine is the lack of individual approach to patients, lack of equipment in the offices of regional ophthalmologists, and lack of specialized glaucoma offices.The tense epidemiological situation during the Covid-19 pandemic, gave understanding that while in-person consultations and remote consultations (telemedicine) cannot replace each other, a combination of these methods is cost-effective, can reduce the uneven distribution of ophthalmic resources, reduce the burden on the doctor and the rate of misdiagnosis. The situation was aggravated by the closure of ophthalmological hospitals and an increase in the waiting time for consultation in higher specialized medical institutions, which probably entails an increase in patients with progression of the glaucomatous process and the economic burden on both the state and the patients themselves.Telemedicine should be gradually introduced into everyday practice, for which it is advisable to create a single database of glaucoma patients to track the glaucomatous process.
- 1 January 2022
- Published by Media Sphere Publishing Group in Russian Annals of Ophthalmology
- Vol. 138 (5) , 66-72
Effectiveness and safety of a hypotensive preservative-free drug in long-term therapy of glaucoma
ЦЕЛЬ ИССЛЕДОВАНИЯ Изучить состояние глазной поверхности и эффективность препарата Тафлотан при длительном применении у пациентов с впервые выявленной первичной открытоугольной глаукомой в реальной клинической практике. МАТЕРИАЛ И МЕТОДЫ Представлены результаты ретроспективного наблюдательного исследования, в которое включались пациенты с впервые выявленной глаукомой, получавшие Тафлотан по 1 капле 1 раз в день вечером в течение 12 мес. Пациентам на старте терапии, через 1 и 12 мес лечения производилось измерение внутриглазного давления (ВГД), показателей светочувствительности сетчатки (MD, PSD), толщины слоя нервных волокон сетчатки (СНВС), оценивалось состояние глазной поверхности с помощью теста Ширмера, пробы Норна, опросника OSDI, измерения высоты слезного мениска и окрашивания роговицы лиссаминовым зеленым. РЕЗУЛЬТАТЫ На фоне применения препарата Тафлотан показатели ВГД у всех пациентов достигли целевых значений через 1 мес после начала лечения, снизившись с 25±4 до 17±3 мм рт.ст. В дальнейшем на фоне лечения уровень ВГД продолжал снижаться, через 12 мес он составил 16±3 мм рт.ст. Показатели светочувствительности сетчатки (MD и PSD) и толщина СНВС через 1 и 12 мес наблюдения статистически значимо не отличались от исходных, и их значения коррелировали со стадией глаукомы. Все показатели состояния глазной поверхности до начала лечения, через 1 и 12 мес терапии статистически значимо не различались. ЗАКЛЮЧЕНИЕ Тафлотан эффективно снижает уровень ВГД у пациентов с впервые выявленной глаукомой, сохраняя стабильными показатели стандартной автоматической периметрии и толщину СНВС, и не ухудшает состояния глазной поверхности в течение 12 мес терапии.
- 1 January 2022
- Published by Media Sphere Publishing Group in Russian Annals of Ophthalmology
- Vol. 138 (5) , 66-72
Effectiveness and safety of a hypotensive preservative-free drug in long-term therapy of glaucoma
ЦЕЛЬ ИССЛЕДОВАНИЯ Изучить состояние глазной поверхности и эффективность препарата Тафлотан при длительном применении у пациентов с впервые выявленной первичной открытоугольной глаукомой в реальной клинической практике. МАТЕРИАЛ И МЕТОДЫ Представлены результаты ретроспективного наблюдательного исследования, в которое включались пациенты с впервые выявленной глаукомой, получавшие Тафлотан по 1 капле 1 раз в день вечером в течение 12 мес. Пациентам на старте терапии, через 1 и 12 мес лечения производилось измерение внутриглазного давления (ВГД), показателей светочувствительности сетчатки (MD, PSD), толщины слоя нервных волокон сетчатки (СНВС), оценивалось состояние глазной поверхности с помощью теста Ширмера, пробы Норна, опросника OSDI, измерения высоты слезного мениска и окрашивания роговицы лиссаминовым зеленым. РЕЗУЛЬТАТЫ На фоне применения препарата Тафлотан показатели ВГД у всех пациентов достигли целевых значений через 1 мес после начала лечения, снизившись с 25±4 до 17±3 мм рт.ст. В дальнейшем на фоне лечения уровень ВГД продолжал снижаться, через 12 мес он составил 16±3 мм рт.ст. Показатели светочувствительности сетчатки (MD и PSD) и толщина СНВС через 1 и 12 мес наблюдения статистически значимо не отличались от исходных, и их значения коррелировали со стадией глаукомы. Все показатели состояния глазной поверхности до начала лечения, через 1 и 12 мес терапии статистически значимо не различались. ЗАКЛЮЧЕНИЕ Тафлотан эффективно снижает уровень ВГД у пациентов с впервые выявленной глаукомой, сохраняя стабильными показатели стандартной автоматической периметрии и толщину СНВС, и не ухудшает состояния глазной поверхности в течение 12 мес терапии.
- Open Access
- 1 October 2021
- Published by PE Polunina Elizareta Gennadievna in Ophthalmology in Russia
- Vol. 18 (3) , 532-538
Prerequisites to Use Preservative-Free Drugs in Medication Therapy of Glaucoma
Purpose — to analyze the literature data on the benefits of preservative-free medication therapy for glaucoma.Materials and methods. 482 articles in the Pubmed database published from 1975 to 2020 were analyzed using the terms: “glaucoma”, “preservatives”, “preservative-free therapy”, “benzalkonium chloride”. The review includes 78 articles. Inclusion criteria: studies that examined the effect of local antihypertensive therapy on the condition of the ocular surface in comparison with preservative-free drugs.Discussion. BAC is the most common preservative used in ophthalmology, accounting for 70 % of eye drop formulations. But it has a pronounced toxic effect on the ocular surface, so other classes of preservatives have been developed. These include polyquaternium-1 detergent; oxidizing preservatives — stabilized oxychlorocomplex and sodium perborate; ionic buffer preservative. However, most of the publications are devoted to BAC, as it is considered the most toxic and, at the same time, the most commonly used preservative. There is a large number of switching studies from preservative therapy to preservative-free, in which almost all groups of drugs used for the treatment of glaucoma were studied, but the use of antihypertensive drugs is associated not only with the action of preservatives, but also with the active substance, excipients and buffers. However, most switching studies demonstrate the benefits of preservative-free drugs. Other studies compared preservative and preservative-free drugs with the same active ingredients, in which a comparable hypotensive effect and safety profile was revealed, which indicates that BAC is not required for adequate penetration of the active substance to the point of application. At the same time, statistically significant advantages in the tolerability of preservativefree therapy were also revealed.Conclusion. Glaucoma preservative therapy has a toxic effect on the ocular surface, which leads to a decrease in the quality of life and compliance. Switching to preservative-free drugs can help reduce iatrogenic complications during long-term treatment of patients with glaucoma
- 1 October 2021
- Published by PE Polunina Elizareta Gennadievna in Ophthalmology in Russia
- Vol. 18 (3) , 532-538
Open AccessPrerequisites to Use Preservative-Free Drugs in Medication Therapy of Glaucoma
Purpose — to analyze the literature data on the benefits of preservative-free medication therapy for glaucoma.Materials and methods. 482 articles in the Pubmed database published from 1975 to 2020 were analyzed using the terms: “glaucoma”, “preservatives”, “preservative-free therapy”, “benzalkonium chloride”. The review includes 78 articles. Inclusion criteria: studies that examined the effect of local antihypertensive therapy on the condition of the ocular surface in comparison with preservative-free drugs.Discussion. BAC is the most common preservative used in ophthalmology, accounting for 70 % of eye drop formulations. But it has a pronounced toxic effect on the ocular surface, so other classes of preservatives have been developed. These include polyquaternium-1 detergent; oxidizing preservatives — stabilized oxychlorocomplex and sodium perborate; ionic buffer preservative. However, most of the publications are devoted to BAC, as it is considered the most toxic and, at the same time, the most commonly used preservative. There is a large number of switching studies from preservative therapy to preservative-free, in which almost all groups of drugs used for the treatment of glaucoma were studied, but the use of antihypertensive drugs is associated not only with the action of preservatives, but also with the active substance, excipients and buffers. However, most switching studies demonstrate the benefits of preservative-free drugs. Other studies compared preservative and preservative-free drugs with the same active ingredients, in which a comparable hypotensive effect and safety profile was revealed, which indicates that BAC is not required for adequate penetration of the active substance to the point of application. At the same time, statistically significant advantages in the tolerability of preservativefree therapy were also revealed.Conclusion. Glaucoma preservative therapy has a toxic effect on the ocular surface, which leads to a decrease in the quality of life and compliance. Switching to preservative-free drugs can help reduce iatrogenic complications during long-term treatment of patients with glaucoma